US › Healthcare

Ultragenyx (RARE)

US · Healthcare · Biotechnology

$25.81+3.16%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$136.0M
Revenue YoY
-2.4%
Net profit
$-185.0M
Profit YoY
-22.5%
EPS
$-1.54
EPS estimate
$-1.46
Net margin
-136.0%

EPS came in at -1.54 against a street estimate of -1.46 — a miss of 5.5%.

Key statistics

Market cap
$2.45B
Forward P/E
0.0
P/B
247.70
Book value
$-2.41
EPS (TTM)
$-6.10
52-week high
$39.89
52-week low
$18.29
50-day MA
$27.40
200-day MA
$27.01
Beta
0.31

Analyst view

Analysts rate Ultragenyx a strong buy (19 buy, 1 hold, 0 sell out of 20) with an average price target of $53.37.

Shareholding

Insiders
3.45%
Institutions
102.16%

Largest institutional holders

FundStake
BlackRock Inc7.41%
Vanguard Portfolio Management, LLC5.47%
State Street Corp5.10%
AQR Capital Management LLC4.65%
Vanguard Capital Management, LLC4.25%
RTW INVESTMENTS, LLC3.70%
Sands Capital Management, LLC3.26%
Sofinnova Ventures3.19%

Recent filings & reports

DocumentDate
Board / officer change · Q2 20262026-05-18
Quarterly report · Q1 20262026-05-06
Results announced · Q2 20262026-05-05
Company announcement · Q2 20262026-04-02
Company announcement · Q1 20262026-03-30
Proxy statement · Q2 20262026-03-27
Annual report FY20252026-02-18
Quarterly report · Q3 20252025-11-05

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Ultragenyx — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.